Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
4
×
cancer
clinical trials
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
cancer immunotherapy
eli lilly
investing
medicare
merck
nivolumab
nonalcoholic steatohepatitis
pembrolizumab keytruda
pfizer
What
bio
drug
4
×
roundup
companies
nash
new
news
advantages
alzheimer’s
annual
approval
approved
assessed
attention
bar
biogen’s
biopharmaceutical
biotech
brings
communities
conference
convo
digital
disease
earlier
epidemic
esmo
europe
expect
failures
fatty
fda
frenzied
gamble
germany
growing
hosted
investment
known
led
Language
unset
Current search:
drug
×
biotech
×
" bristol-myers squibb "
×
" clinical trials "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More